The Vaccines Microbicides Resource Tracking Working Group, comprised of AVAC, the International AIDS Vaccine Initiative (IAVI), and the Joint United Nations Programme on HIV/AIDS (UNAIDS), uses a comprehensive methodology to track annual research and development investment trends in biomedical HIV prevention.
From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape
Ending AIDS Gamechangers
From the Ending AIDS report, a joint partnership between AVAC and amfAR. Visit www.endingaids.org for more information.
Trial Participants as Research Investors
ARV-Based Prevention Research and Development Product Pipeline
The Px Wire centerspread from April-June 2013 Volume 6, No. 2 showcases the ARV-based HIV prevention pipeline from pre-clinical research to implementation projects.
Achieving the End: One Year and Counting
In AVAC Report 2012, Achieving the End: One Year and Counting we’ve identified five priorities for action.
Microbicide Clinical Trial Participants by Region
This graphic from AVAC’s Microbicides by the Numbers one-pager shows the prominent role played by African trial participants in microbicide research.
The Importance of Location and Population to the HIV Response
This graphic from AVAC’s Microbicides by the Numbers one-pager shows on which populations the burden of the epidemic falls in different regions.
Global Prevention Research Advocacy Partnerships
This map from the AVAC Report 2012 identifies global prevention research advocacy partnerships.
Achieving the End
Recent breakthroughs in HIV prevention research have created unprecedented opportunities to curb new HIV infections, save lives and set the world on a path towards eliminating HIV transmission.
Key Strategies for Closing Gaps in the HIV Treatment U=U Cascade
From the AVAC Report 2012, this infographic highlights an AVAC 2013 priority of articulating and funding a retention science agenda that narrows the gaps in the Treatment U=U cascade.